Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2023/11/29/2787495/0/en/Valo-Therapeutics-Announces-Regulatory-Approval-to-Expand-Phase-I-Immuno-oncology-Trial-into-Sarcoma.html
https://www.globenewswire.com//news-release/2023/10/10/2757151/0/en/Valo-Therapeutics-Announces-Acquisition-of-Bruker-Corporation-s-Latest-Mass-Spectrometer-Platform-for-Tumor-Antigen-Identification-with-ValoTx-s-PeptiCHIP-Technology.html
https://www.globenewswire.com/news-release/2023/06/13/2686829/0/en/Valo-Therapeutics-and-Texcell-Announce-Research-Collaboration-to-Evaluate-Immune-Responses-to-PeptiCRAd-1-in-Phase-I-Clinical-Study.html
https://www.globenewswire.com/news-release/2023/05/23/2673952/0/en/Valo-Therapeutics-Announces-First-Patient-Dosed-with-PeptiCRAd-1-Innovative-Immuno-oncology.html
https://www.globenewswire.com/news-release/2023/02/16/2609376/0/en/Valo-Therapeutics-Announces-Two-European-Patents-Granted-for-its-Lead-Asset-PeptiCRAd-1-in-Immuno-Oncology.html
https://www.globenewswire.com/news-release/2023/02/14/2607271/0/en/Valo-Therapeutics-Secures-EUR-2-23-million-from-the-European-Innovation-Council-to-Progress-Innovative-PeptiCHIP-Technology.html
https://www.globenewswire.com/news-release/2023/01/11/2586724/0/en/Valo-Therapeutics-selects-Exothera-to-develop-large-scale-oncolytic-Adenovirus-manufacturing.html
https://www.prnewswire.com/news-releases/valo-therapeutics-announces-scientific-advisory-board-301596980.html
https://www.prnewswire.com/news-releases/valo-therapeutics-acquires-peptichip-technology-enabling-rapid-identification-of-tumor-antigens-for-the-development-of-personalized-immunotherapies-301592355.html